SomaSignal™ test portfolio
By measuring 7,000 proteins from a 55-µL sample with high throughput and reproducibility, you uncover insights into disease pathways and pinpoint new treatment targets.
Translating proteins into critical health information
Genetics reveal ancestry and lifetime risk of disease development, acting as the body’s initial instruction manual. Proteins, on the other hand, act as building blocks, messengers, and workers throughout a patient’s lifetime. Genes can’t shed light on current health status, or how lifestyle and environment are affecting your patients’ health. But proteins can.
Using the first and only technology that can simultaneously find and measure nearly 7,000 human proteins, the SomaScan® platform offers a readout of your patients’ “real-time” health status including risks for conditions such as cardiovascular and renal disease and indicators of future illness (e.g., kidney function, glucose levels and more).
With one simple blood test, SomaSignal tests can evaluate the following systems and conditions:
4 year risk of heart attack, stroke, or heart failure
4 year risk of heart attack, stroke, or heart failure following an initial event
Heart Failure reduced Ejection Fraction: 12 months
Risk of death in 1 year with stable HFrEF
Heart Failure preserved Ejection Fraction: 12 months
Risk of death in 1 year with stable HFpEF
Percent body fat
Resting energy rate
Calories burned at rest
Lean body mass
Total lean body mass
Blood glucose levels
following sugar intake
Presence/absence of excess liver fat
Fat content around vital organs
Aerobic fitness level (VO2 Max)
Predicted weekly alcohol consumption
Predicts the relative risk of developing kidney disease
Estimates the glomerular filtration rate
Risk of Dementia diagnosis within 20 years
Thousands of proteins analyzed together paint a better picture of patient health than genes or single protein tests.
SomaSignal™ tests are developed and their performance characteristics are determined by SomaLogic Operating Co, Inc. They have neither been cleared nor approved by the US Food and Drug Administration (FDA). SomaLogic operates a Clinical Laboratory Improvement Amendments (CLIA) certified, and College of American Pathologists (CAP) accredited laboratory.